Delivery Order SPE2DB22D1103-SPE2DB25FH2F6
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,345.60 to AmerisourceBergen Drug Corp for the supply of Trelegy Ellipta 100-62.5-25 inhalers (60-count). This contract, awarded on August 4, 2025, with an ultimate completion date of August 5, 2025, represents a firm fixed-price delivery order with no set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,154.61 to AmerisourceBergen Drug Corp for Trelegy Ellipta 200-62.5-25 inhalers (60-count units). This competitively awarded, firm fixed-price delivery order was issued on August 19, 2025, with an ultimate completion date of August 20, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Trelegy Ellipta 200-62.5-25 inhalers (60-count units) with a ceiling value of $1,867.66 and an ultimate completion date of August 1, 2025. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award was made...
- The Defense Logistics Agency awarded a delivery order valued at $7,178.56 to AmerisourceBergen Drug Corp for Trelegy Ellipta 100-62.5-25 inhalers (60-count), with an ultimate completion date of August 26, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement and will be performed at the company's corporate office in Conshohocken, Pennsylvania. Trelegy Ellipta is a prescription maintenance inhaler used to treat chronic obstructive pulmonary...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,303.11 to AmerisourceBergen Drug Corp for Trelegy Ellipta 200-62.5-25 inhalers (60-count units) on August 4, 2025, with completion scheduled for August 5, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and is being fulfilled at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $25,630.25 to AmerisourceBergen Drug Corp for Trelegy Ellipta 200-62.5-25 inhalers (60-count units) on August 7, 2025, with completion scheduled for August 8, 2025. This non-competitive, firm fixed-price delivery order was placed against AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December 2026. The product...
- The Defense Logistics Agency awarded a delivery order valued at $16,076.36 to AmerisourceBergen Drug Corp for Trelegy Ellipta 200-62.5-25 inhalers (60-count) on September 12, 2025, with an ultimate completion date of September 15, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract issued under...
- The Defense Logistics Agency awarded a delivery order valued at $21,488.46 to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Trelegy Ellipta 100-62.5-25 inhalers (60-count package). This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of July 30, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate office and serves as a major...
- The Defense Logistics Agency awarded a delivery order valued at $10,197.08 to AmerisourceBergen Drug Corp for Trelegy Ellipta 100-62.5-25 inhalers (60-count) on September 12, 2025, with an ultimate completion date of September 15, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The product is a combination maintenance and reliever inhaler...
- The Defense Logistics Agency awarded a $16,902.11 delivery order to AmerisourceBergen Drug Corp for Trelegy Ellipta 200-62.5-25 inhalers (60-count units) on August 13, 2025, with completion scheduled for August 14, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The pharmaceutical products will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major...
- SPE2DB22D1103Indefinite Delivery Contract
- SPE2DB22D1103-SPE2DB25FH2F6Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Trelegy Ellipta 100-62.5-25 inhalers (60-count) on September 12, 2025, with a ceiling value of $4,687.45 and an ultimate completion date of September 15, 2025. This is a firm fixed-price delivery order with no set-aside designation, awarded competitively to the prime contractor under an existing contract vehicle. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement extending through December 2026 that supports pharmaceutical procurement across the Department of Defense and federal healthcare systems. Trelegy Ellipta is a combination respiratory medication used for managing chronic obstructive pulmonary disease (COPD), consistent with AmerisourceBergen's role as a major pharmaceutical distributor supplying brand-name and generic medications, vaccines, and medical supplies to military and federal healthcare programs worldwide. The company's extensive federal contract portfolio demonstrates its capability to fulfill diverse medical procurement requirements through competitive open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.7k | 9/12/25 |